Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oAd + LP
- Development stage
- Preclinical
- Lead developer
- GeneMedicine
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
oAd + LP is an experimental therapeutic formulation consisting of an oncolytic adenovirus (oAd) encapsulated within a lipid envelope (liposome). In the specific research context provided, the oAd is engineered to co-express short-hairpin RNA (shRNA) against Wnt5 (shWnt5) and the proteoglycan decorin to enhance antitumor efficacy. The liposomal encapsulation (LP) is designed to protect the viral particles from systemic clearance and reduce non-specific accumulation in the liver, which are common limitations of systemic oncolytic virotherapy. While this formulation lacks the advanced pH-responsive and EGFR-targeting modifications of related variants (such as oAd/LP-GE-PS), it serves as a foundational delivery system that demonstrates improved safety profiles and attenuated hepatic toxicity compared to naked adenovirus in preclinical models of EGFR-positive breast cancer.
- Other names
- liposomal oncolytic adenovirusliposome-encapsulated oncolytic adenovirus
02
Targets
DCN (Decorin)VLDL (Very low-density lipoprotein)WNT5A (Protein Wnt-5a)
Beyond the preview
Go deeper on oAd + LP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oAd + LP.